Wednesday, October 22, 2014 Last update: 6:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Formula Pharmaceuticals Appoints Dr. Daniel D. Von Hoff as Chairman of the Scientific Advisory Board

Companies mentioned in this article: Formula Pharmaceuticals, Inc.

BERWYN, Pa. -- (BUSINESS WIRE) -- Formula Pharmaceuticals, Inc. announces the appointment of Daniel D. Von Hoff, MD, FACP, as Chairman of the company's Scientific Advisory Board.

Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute), Phoenix, AZ. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute and holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.

Dr. Von Hoff served on the National Cancer Advisory Board from 2004-2010. He is a past President of the American Association of Cancer Research (AACR), Fellow of the American College of Physicians (FACP), and a member and past board member of the American Society of Clinical Oncology (ASCO). He is a founder of ILEX™ Oncology, Inc., subsequently acquired by Genzyme. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs: The Journal of New Anti-Cancer Agents and of Molecular Cancer Therapeutics.

Dr. Von Hoff has published more than 600 papers and 135 book chapters. He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care.

"We are extremely pleased to welcome Dr. Von Hoff as Chairman of our Scientific Advisory Board. Dr. Von Hoff is a world recognized oncology expert, with a dedicated interest in breakthrough therapeutic approaches. We look forward to advancing our cancer immunotherapy program with Dr. Von Hoff’s leadership within our Scientific Advisory Board,” said Maurits W. Geerlings, Chief Executive Officer of Formula Pharmaceuticals.

“There is a strong scientific and clinical rationale for Formula’s immunotherapy approach,” said Dr. Von Hoff. “Their first agent, FPI-01, can be developed both as a stand-alone therapy and in combination with existing and novel treatment modalities. I look forward to contributing to the development of this new approach, and to working closely with Formula’s distinguished team, some of whom I have known and worked with for several years.”

About Formula Pharmaceuticals

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in multiple myeloma (MM), acute myeloid leukemia (AML) and other cancers and cancer settings. Formula has assembled a world-class scientific, clinical development and business team well positioned to maximize the clinical and commercial value of promising drug candidates through excellence in drug development and strategic partnering. For more information, visit www.formulapharma.com.


Copyright © Business Wire 2014
Contact:

Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com